Heart and Vascular Center, Department of Cardiology, Semmelweis University, Városmajor str. 68, H-1122 Budapest, Hungary.
Int J Mol Sci. 2021 Sep 12;22(18):9852. doi: 10.3390/ijms22189852.
Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of hospitalization for heart failure in patients with or without type 2 diabetes (T2DM) in large-scale clinical trials. The exact mechanism of action is currently unclear. The dual SGLT1/2 inhibitor sotagliflozin not only reduced hospitalization for HF in patients with T2DM, but also lowered the risk of myocardial infarction and stroke, suggesting a possible additional benefit related to SGLT1 inhibition. In fact, several preclinical studies suggest that SGLT1 plays an important role in cardiac pathophysiological processes. In this review, our aim is to establish the clinical significance of myocardial SGLT1 inhibition through reviewing basic research studies in the context of SGLT2 inhibitor trials.
选择性钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在大规模临床试验中降低了有或没有 2 型糖尿病（T2DM）的心力衰竭住院风险。其确切的作用机制目前尚不清楚。双重 SGLT1/2 抑制剂索格列净不仅降低了 T2DM 患者的 HF 住院风险，还降低了心肌梗死和中风的风险，这表明 SGLT1 抑制可能具有额外的益处。事实上，几项临床前研究表明 SGLT1 在心脏病理生理过程中发挥重要作用。在这篇综述中，我们旨在通过审查 SGLT2 抑制剂试验背景下的基础研究来确定心肌 SGLT1 抑制的临床意义。
